Lowest Price Guaranteed From USD 4,799
Companies Covered
187
Slides
131
View Count
8555
The complement inhibitors market is estimated to be worth $6.8 billion in 2022 and is expected to grow at CAGR of over 15% during the forecast period. Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA. In addition, the complement inhibitor drug, EMPAVELITM (pegcetacoplan), which is the first approved complement C3 inhibitor, developed by Apellis Pharmaceuticals, has been approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria; it is believed to bring in new possibilities for the treatment of autoimmune and inflammatory disorders. Discovered in 19th century, complement system is a part of innate immune system and tissue homeostasis, which recognizes, tags and helps to eliminate various disease-causing pathogens. In addition, complement system plays a role in the physiology of a healthy organism (homeostasis) for the removal of apoptotic cells, thereby regulating cell survival. However, inadequate complement activation results in outgrowth of pathogens and suppression of complement regulators, which ultimately becomes a disease cause. As a result, complement-targeted therapeutics have been developed; they inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.
Several drug developers are actively engaged in the development of next generation complement therapeutics with enhanced efficacy. A variety of molecules, such as biologics, gene therapies, oligonucleotides, small interfering RNAs and small molecule-based complement therapeutics are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders. Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future. Moreover, the R&D efforts in this field are also being supported by the National Institutes of Health, which have awarded grants worth USD 837 million for research efforts in this domain over the last few years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of the complement therapeutics is likely to expand. Further, with the encouraging clinical research efforts, broadening of disease focus and efforts to go beyond C5 with innovative approaches that could decrease prices and address safety concerns, the complement therapeutics market is poised to witness steady market growth over the coming years.
![]() |
![]() |
![]() |
Examples of key companies engaged in complement inhibitors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda and UCB. This market report includes an easily searchable excel database of all the companies developing complement inhibitors, worldwide.
Several recent developments have taken place in the field of complement inhibitors market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Complement Inhibitors Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035’ market report features an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the complement inhibitors market. The market research report underlines an in-depth analysis, highlighting the diverse capabilities of players engaged in complement inhibitors market.
![]() |
![]() |
![]() |
Amongst other elements, the market research report includes:
![]() |
![]() |
![]() |
The key objective of complement inhibitors market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for complement inhibitors market during the forecast period. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the forecast period 2022-2035.
Our year wise projections of the current and forecasted opportunity within the complement inhibitors market have further been segmented across [A] Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), [B] Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), [C] Type of Molecule (Biologics and Small Molecules), [D] Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), [E] Type of Therapy (Monotherapy and Combination Therapy), [F] Route of Administration (Intravenous, Oral and Subcutaneous), [G] Key Geographical Regions (North America, Europe and Asia-Pacific. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.